Background and Objectives: Long-acting somatostatin analogues (SSA) (octreotide LAR and lanreotide Autogel) are recommended as first line treatment of locally advanced or metastatic well-differentiated neuroendocrine tumors (NETs) with a good expression of somatostatin receptor (SSTR). Both of these SSAs are usually administered via injections repeated every 4 weeks. The purpose of the study was to compare the route of SSA administration (injection performed by professional medical staff and self-administration of the drug) with progression-free survival. Materials and methods: 88 patients in 2019 and 96 patients in 2020 with locally advanced or metastatic well-differentiated NETs were included in the study. All patients had a good expression of SSTR type 2 and had been treated for at least 3 months with a stable dose of long-acting somatostatin analogue every 4 weeks. All of them had received training on drug self-injections from professional NET nurses at the beginning of the COVID-19 epidemic. Results: The rate of NET progression in the study group in 2020 was higher than in 2019 29.1% vs. 18.1% (28 vs. 16 cases), p = 0.081. Conclusions: The method of administration of long-acting SSA injection performed by professional medical staff vs. self-injection of the drug may significantly affect the risk of NET progression. The unequivocal confirmation of such a relationship requires further observation.

No abstract

Introduction The number of detected pancreatic neuroendocrine tumors (PanNETs) is increasing over the last decades. Surgical resection remains the only potentially curative treatment, yet the management is still controversial. This study aimed to compare patients after radical PanNET G2 resection to determine the most important predictive factors for relapse. Material and methods All patients with histologically confirmed PanNET G2 who underwent the successful surgery between 2006-2020 with intention of radical treatment were enrolled. Results There was forty-four patients eligible for the analysis. The average follow-up was 8.39±4.5 years. The disease recurrence was observed in 16 (36.36%) patients. The dominant location of the primary tumor was the tail of the pancreas (43.18%), especially in the subgroup with the disease recurrence (56.25%). The relationship between the largest dimension of the tumor with a division of <4 cm vs >4 cm and the relapse was close to statistical significance (p=0.077). Recurrence was associated with a larger tumor size (p=0.018). There was a statistically significant relationship and a weak correlation between Ki-67 (p=0,036, V Cramer=0,371) and disease relapse. Conclusion The most important predictive factors of the NET G2 recurrence after radical surgery were Ki67 over 5% and the largest dimension of tumor over 4cm.

No abstract

No abstract